EuroPCR

PCR is a European organization dedicated to education and information in the field of interventional cardiology and minimally invasive transcatheter procedures. Its activities cover a large spectrum, from the organization of annual courses in Europe, Asia, the Middle East and Africa, to editing a scientific journal, publishing textbooks as well as providing training seminars on thematic subjects. For more information, visit https://www.pcronline.com/Courses/EuroPCR.

Meril TAVR valves linked to 1-year outcomes similar to industry-leading devices from Medtronic, Edwards
Indian medtech company Meril Life Sciences has been manufacturing its Myval TAVR valves for years, but FDA approval has remained out of reach. These latest data represent a one-year update of the multicenter LANDMARK clinical trial.
Cardiologist shares positive first-in-human data on TriCares TTVR device
The new Topaz TTVR system was associated with the consistent elimination of tricuspid regurgitation. In addition, none of the first 20 patients treated with the device required a permanent pacemaker as a result of the procedure.
Early TAVR or SAVR in asymptomatic patients linked to improved survival, reduced costs
Researchers explored data from more than 24,000 AVR patients, presenting their findings at EuroPCR in Paris.
Cardiology, radiology specialists debate CCTA’s rise as a go-to imaging modality for CAD
CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.
Medtronic TAVR valves at heart of key studies presented during PCR London Valves 2024
One study presented during the three-day conference focused on the potential benefits of an optimized TAVR pathway. Another study, meanwhile, tracked changes in paravalvular leak severity over time.

Meril TAVR valves linked to 1-year outcomes similar to industry-leading devices from Medtronic, Edwards

Indian medtech company Meril Life Sciences has been manufacturing its Myval TAVR valves for years, but FDA approval has remained out of reach. These latest data represent a one-year update of the multicenter LANDMARK clinical trial.

Topaz transcatheter tricuspid valve replacement (TTVR) system TriCares

Cardiologist shares positive first-in-human data on TriCares TTVR device

The new Topaz TTVR system was associated with the consistent elimination of tricuspid regurgitation. In addition, none of the first 20 patients treated with the device required a permanent pacemaker as a result of the procedure.

Early TAVR or SAVR in asymptomatic patients linked to improved survival, reduced costs

Researchers explored data from more than 24,000 AVR patients, presenting their findings at EuroPCR in Paris.

Cardiology, radiology specialists debate CCTA’s rise as a go-to imaging modality for CAD

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

Medtronic's Evolut Pro TAVR valve treating aortic stenosis

Medtronic TAVR valves at heart of key studies presented during PCR London Valves 2024

One study presented during the three-day conference focused on the potential benefits of an optimized TAVR pathway. Another study, meanwhile, tracked changes in paravalvular leak severity over time.

The use of intravascular lithotripsy (IVL) during percutaneous coronary intervention (PCI) is still safe and effective when patients present with calcified nodules (CNs), according to new long-term data published in EuroIntervention.[1] Researchers compared outcomes from patients with and without CNs, highlighting key similarities in stent expansion and luminal gain.

Shockwave Medical’s IVL technology still safe, effective in patients with calcified nodules

Intravascular lithotripsy is still a safe and effective frontline preparation tool when PCI patients present with calcified nodules, a new two-year study confirmed. Researchers focused on stent expansion and luminal gain, among other key data points.

Newest TAVR valve from Edwards linked to better 1-year outcomes than its predecessors

The Sapien 3 Ultra Resilia TAVR valve from Edwards Lifesciences is associated with a significantly higher survival rate after one year than the company's previous balloon-expandable valves. Researchers identified other key benefits as well, sharing their findings in JACC: Cardiovascular Interventions.

Redo TAVR: A 26-mm Sapien 3 device (Edwards Lifesciences) implanted within a 29-mm CoreValve device (Medtronic). Image courtesy of EuroIntervention.

Redo TAVR: The impact of implanting balloon-expandable valves in failed self-expanding valves

Researchers took a closer look at the effectiveness of redo TAVR, implanting Sapien 3 valves into a variety of explanted CoreValve and Evolut valves.